hydroxyurea

P2, N=107, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Feb 2026

ZC granules may be a potential therapy for alleviating HU-induced DOR.

The most used agents include hydroxyurea, interferon, hypomethylating agents, and JAK inhibitors, although none of them are disease-modifying. Allogeneic hematopoietic stem cell transplant remains the only potentially curative approach and should be considered in all eligible patients. Actionable mutations (CSF3R, NRAS/KRAS, and KIT) have also been identified, supporting the development of new agents targeting the involved pathways.

Statistically significant interactions existed between COPD/asthma, female sex (HR 3.94, 95% CI 1.01-11.02), ET phenotype (HR 7.1, 95% CI 15.3-16.7), JAK2 positive status (HR 4.17, 95% CI 1.04-6.9), hydroxyurea use (HR 4.67, 95% CI 1.10-7.43), and the presence of other cardiovascular risk factors (HR 8.1, 95% CI 1.55-10.72) with overall thrombotic risk (interaction p < 0.050 for all analyses)...There was no effect of COPD/asthma on overall survival. These results provide an important signal regarding the potentially inferior outcomes in ET/PV patients presenting with these common respiratory disorders and may help to further personalize MPN management.

By comparing the cellular responses to pyridostatin and hydroxyurea, respectively, we confirmed that p53S specifically regulates G4-related DNA replication stress...Together, our data indicate that certain tumorigenic features can be applied to balance with premature aging, rescuing the aging phenotype without tumor risk. This study suggests a new mechanism in aging regulation and provides the possibility of developing a tumor-free longevity strategy and targeting G4 and DNA replication in aging-related tumor therapy.

P4, N=76, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jun 2026 --> Jan 2027

P3, N=340, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Sep 2026 --> Jul 2027

P2, N=60, Active, not recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd

P2, N=153, Not yet recruiting, RTOG Foundation, Inc. | Initiation date: Aug 2025 --> Nov 2025

P3, N=300, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2029 --> Mar 2028

Anagrelide (ANA), α-interferon (IFN) and ruxolitinib (Ruxo) increased, while hydroxyurea (HU) decreased platelet size. Anagrelide-induced abnormalities are reverted by RANTES addition. RANTES plasmatic levels and platelet RNA expression are decreased in anagrelide-treated vs untreated patients, suggesting in vitro findings could reflect anagrelide action in vivo.

ET can also lead to PHT, portal vein thrombosis, and esophageal varices. Clinicians should consider these possibilities when dealing with such patients.